1. Effect of patient decision aids on decisional conflict and regret associated with breast cancer surgery: a randomized controlled trial.
- Author
-
Lin SQ, Su CM, Wu HC, Chou YY, Yen YC, and Tam KW
- Subjects
- Decision Making, Decision Support Techniques, Emotions, Female, Humans, Breast Neoplasms surgery, Mastectomy
- Abstract
Background: Patients with breast cancer encounter difficulties in making surgical treatment decisions. Shared decision-making (SDM) with patient decision aids (PDAs) can minimize patients' decisional conflicts. However, the effect of PDAs in Asia remains inconclusive. This study investigated the effect of SDM assisted by PDAs on the decisional conflict of patients with breast cancer., Methods: In this two-group, outcome assessor-blind, randomized controlled trial, 151 patients diagnosed as having breast cancer were assigned to the PDA (SDM with PDA) group or the standard (SDM without PDA) group. Demographic and clinical variables were analyzed to identify variables affecting the treatment choice. The patients' decision-making difficulties were evaluated using the four-item SURE scale during preoperative hospitalization, and decisional conflicts were examined using the five-item Decision Regret scale and Hospital Anxiety and Depression Scale (HADS) 1 month after surgery., Results: The choice of breast conservation therapy and mastectomy did not significantly differ between the PDA and standard groups. The PDA group had a higher level of depression after making decisions (Pā=ā0.029) than did the standard group. No significant difference in the total scores of the SURE scale and Decision Regret scale were noted between the groups., Conclusion: PDAs did not assist the patients with breast cancer in making breast surgery-related decisions. Clinicians should focus on SDM grounded in evidence-based medicine with care and help patients consider their individual preferences., Trial Registration: ClinicalTrial.gov, NCT03105076; April 7, 2017 ( http://www., Clinicaltrials: gov )., (© 2022. The Author(s), under exclusive licence to The Japanese Breast Cancer Society.)
- Published
- 2022
- Full Text
- View/download PDF